Drug Profile
BPZE 1
Alternative Names: BPZE-1; Pertussis vaccine - ILiADLatest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator INSERM; Institut Pasteur
- Developer ILiAD Biotechnologies; INSERM; Institut Pasteur; National Institute of Allergy and Infectious Diseases
- Class Attenuated vaccines; Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pertussis
Most Recent Events
- 26 Oct 2023 ILiAD Biotechnologies completes a phase-II CHAMPION-1 clinical trials in Pertussis (Prevention, In adults) in United Kingdom (Intranasal) (NCT05461131)
- 05 Sep 2023 Immunogenicity and adverse events data from the phase IIb CHAMPION-1 trial in Pertussis released by ILiAD Biotechnologies
- 05 Sep 2023 ILiAD Biotechnologies plans a phase III human challenge trial for Pertussis